Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?

J Thorac Oncol. 2021 Oct;16(10):e77. doi: 10.1016/j.jtho.2021.06.018.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • ErbB Receptors
  • Follow-Up Studies
  • Humans
  • Lung Neoplasms*

Substances

  • ErbB Receptors